Scholarlink

Background <p>Elevated glucose levels have emerged as a significant prognostic factor following acute myocardial infarction (AMI).</p> Objective <p>This study aimed to evaluate glycemic parameters associated with infarct size and left ventricular function.</p> Research design and methods <p>A total of 244 patients with ST-segment elevation myocardial infarction (STEMI) treated using a pharmacoinvasive strategy were included. Glucose delta was calculated as the difference between mean glucose levels estimated from glycated hemoglobin (HbA1c) and serum glucose levels collected at hospital admission. Infarct size and left ventricular ejection fraction (LVEF) were assessed 30&#xa0;days post-infarction using cardiac magnetic resonance (CMR) imaging.</p> Results <p>Higher glucose delta values were significantly associated with reduced LVEF and larger infarct size, regardless of diabetes diagnosis. Differences in infarcted ventricular mass were noted between diabetic and non-diabetic patients above specific thresholds: (18.62 ± 11.0&#xa0;g) vs. (16.24 ± 13.17&#xa0;g), <i>p</i> = <i>0.019</i>, with an effect size of 0.55. The receiver operating characteristic curve yielded an area under the curve (AUC) of 0.65 (95% CI 0.57–0.72).</p> Conclusions <p>In STEMI patients undergoing pharmacoinvasive treatment, a higher glycemic delta was associated with greater infarct size and lower LVEF. This straightforward glycemic parameter provides valuable prognostic insight for both diabetic and non-diabetic populations.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impact of elevated glucose levels on cardiac function in STEMI patients: glucose delta as a prognostic biomarker

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月10日

查看全文
  • Bernardo F. Garcia,
  • Francisco A. Fonseca,
  • Maria C. Izar,
  • Gilberto Szarf,
  • Attilio Galhardo,
  • Ibraim M. Pinto,
  • Adriano M. Caixeta,
  • Adriano P. Barbosa,
  • Henrique T. Bianco

摘要

Background

Elevated glucose levels have emerged as a significant prognostic factor following acute myocardial infarction (AMI).

Objective

This study aimed to evaluate glycemic parameters associated with infarct size and left ventricular function.

Research design and methods

A total of 244 patients with ST-segment elevation myocardial infarction (STEMI) treated using a pharmacoinvasive strategy were included. Glucose delta was calculated as the difference between mean glucose levels estimated from glycated hemoglobin (HbA1c) and serum glucose levels collected at hospital admission. Infarct size and left ventricular ejection fraction (LVEF) were assessed 30 days post-infarction using cardiac magnetic resonance (CMR) imaging.

Results

Higher glucose delta values were significantly associated with reduced LVEF and larger infarct size, regardless of diabetes diagnosis. Differences in infarcted ventricular mass were noted between diabetic and non-diabetic patients above specific thresholds: (18.62 ± 11.0 g) vs. (16.24 ± 13.17 g), p = 0.019, with an effect size of 0.55. The receiver operating characteristic curve yielded an area under the curve (AUC) of 0.65 (95% CI 0.57–0.72).

Conclusions

In STEMI patients undergoing pharmacoinvasive treatment, a higher glycemic delta was associated with greater infarct size and lower LVEF. This straightforward glycemic parameter provides valuable prognostic insight for both diabetic and non-diabetic populations.

Graphical Abstract